Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSelma SorriKKKerttu KalanderSLSirpa Leppä

Discussion

Loading...

Member takes

Overview

Analysis reveals immune dynamics and CAR-T cell profiles in relapsed B-cell lymphoma, suggesting future targeting strategies.

Key Points

  • Distinct immune profiles were observed in patients with relapsed/refractory B-cell lymphoma after CAR-T therapy.
  • Single cell RNA-sequencing revealed important dynamics in T-cell subsets and clonotypic diversity.
  • Differences in CD4 and CD8 T cell proportions correlated with treatment responses and toxicity trends.
  • Findings indicate that tailored approaches in CAR-T therapy may improve outcomes for specific patient populations.

Cite This Study

Sorri et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3f9https://doi.org/10.1182/blood-2025-2342
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation of T cell fitness of apheresis products with response to CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma: A prospective observational study at a single center2025
  2. 2Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma2025 · 3 citations
  3. 3Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)2025
  4. 4Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma2025
  5. 5CAR-T efficacy in large B-cell lymphoma is shaped by neoantigen-driven epitope spreading and limited by HLA loss and genomic instability2025 · 1 citations